Program
Fluorine F 18 FAPI-74
Its studies are mostly in Esophageal Neoplasms · Gastrointestinal Neoplasms, led by SOFIE.
Furthest: phase 3, since Oct 14, 20253 company-led studies, 2 open or runningNext primary completion: Aug 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SOFIE | 32 open or running | phase 3since Oct 14, 2025 | Nov 29, 2022 | Aug 30, 2027phase 3 · NCT07217704 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2022First study: phase 2 study in Gastrointestinal NeoplasmsFirst studyNCT05641896 · 112 enrolled · United States
- Oct 14, 20252 phase 3 studiesNCT07217717, NCT07217704
Ahead
- Aug 30, 2027Primary completion: phase 3 study in Esophageal NeoplasmsNCT07217704
- Dec 31, 2027Primary completion: phase 3 study in Pancreatic Ductal Adenocarcinoma (PDAC)NCT07217717
TargetBeta
FAP →read by rule
“A radioconjugate composed of FAPI-74, a quinoline-based fibroblast activation protein (FAP)-targeted tracer belonging to the group of FAP inhibitors (FAPi) ”NCIt, by rule
Other programs on FAP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Fluorine F 18 FPyQCPrule | Bracco | phase 2 | 1 |
| HRS-6768 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-FAP Antibody-drug Conjugate OMTX705rule | oncomatryx-biopharma-s-l | phase 1 | 2 |
| Gallium Ga 68 NNS309 | Novartis | phase 1 | 2 |
| Actinium Ac 225 RTX-2358rule | ratio-therapeutics-inc | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713rule | Eli Lilly | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050rule | Immunome | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07217717Pancreatic Ductal Adenocarcinoma (PDAC) · United States | 3 | Recruiting | Dec 31, 2027 | 200 |
| NCT07217704Esophageal Neoplasms · United States | 3 | Recruiting | Aug 30, 2027 | 200 |
| NCT05641896Gastrointestinal Neoplasms · United States | 2 | Completed | Jun 30, 2025 | 112 |
How it is read
Names in the registry
- “[18F]FAPI-74 PET/CT”, 3 entries
Conditions, from the studies’ own filings
- Esophageal Neoplasms, 1 study
- Gastrointestinal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.